Tobira Therapeutics, Inc. (TBRA) [Rocket]

In millions, except per share items	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	-11.9
Revenue growth				-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	25.9
Gross profit	0.0	0.0	0.0	0.0	-37.8
Gross margin					318.7%
Selling, general and administrative [+]	10.9	7.8	2.8	12.2	7.0
General and administrative	10.9	7.8	2.8		7.0
Research and development	24.7	12.2	12.4
Other operating expenses				-12.2	-25.9
EBITDA [+]	-35.4	-20.0	-15.2	0.4	-18.8
EBITDA growth	77.4%	31.7%	-3521.9%	-102.4%
EBITDA margin					158.3%
Depreciation	0.1	0.1	0.0	0.0	0.1
EBITA	-35.5	-20.0	-15.2	0.4	-18.9
EBITA margin					159.4%
Amortization of intangibles				0.4
EBIT [+]	-35.5	-20.0	-15.2	0.0	-18.9
EBIT growth	77.5%	31.9%		-100.0%
EBIT margin					159.4%
Non-recurring items [+]	17.3
Asset impairment	17.3
Interest expense, net [+]	3.1	5.0	3.7		0.3
Interest expense	3.1	5.0	3.7	0.9	0.3
Interest income					0.0
Other income (expense), net [+]	1.9	1.2	0.3	0.9
Change in fair value of warrants	1.9	1.2	0.3
Other				-0.9
Pre-tax income	-54.0	-23.8	-18.6	0.0	-19.2
Income taxes	-4.4	0.3	0.0	0.0	0.0
Tax rate	8.1%		0.0%		0.0%
Net income	-49.6	-24.1	-18.6	0.0	-19.2
Net margin					161.8%

Basic EPS [+]	($4.08)	($59.72)	($47.31)	$0.00	($86.86)
Growth	-93.2%	26.2%		-100.0%
Diluted EPS [+]	($4.08)	($59.72)	($47.31)	$0.00	($86.86)
Growth	-93.2%	26.2%		-100.0%

Shares outstanding (basic) [+]	12.2	0.4	0.4	0.2	0.2
Growth	2915.4%	2.7%	77.6%	0.1%
Shares outstanding (diluted) [+]	12.2	0.4	0.4	0.2	0.2
Growth	2915.4%	2.7%	77.6%	0.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.